TABLE 6.

Comparison of HCMV antigenemia, viremia, and leukoDNAemia levels in HCMV-positive, NASBA-positive versus HCMV-positive, NASBA-negative blood samples from patients in group I (NASBA-positive patients) by type of transplant

HCMV assay	Transplant patient population	Median HCMV level (range) in HCMV-positive blood samples		Pa
		NASBA positive	NASBA negative
Antigenemia quantitation	HTR	16.0 (0–580) (n = 56)	1.0 (0–38) (n = 43)	0.0000
	LTR	10.0 (0–270) (n = 43)	2.0 (0–27) (n = 41)	0.0002
	BMTR	8.0 (0–118) (n = 25)	1.0 (0–25) (n = 38)	0.0015
Viremia quantitation	HTR	0 (0–78) (n = 55)	0 (0–8) (n = 43)	0.0277
	LTR	0 (0–24) (n = 43)	0 (0–5) (n = 41)	>0.05
	BMTR	0 (0–40) (n = 24)	0 (0–5) (n = 36)	>0.05
LeukoDNAemia quantitation	HTR	315.0 (10–10,000) (n = 55)	65.0 (5–10,000) (n = 42)	0.0002
	LTR	285.0 (5–7,900) (n = 43)	85.0 (5–390) (n = 41)	0.0002
	BMTR	150.0 (5–6,940) (n = 25)	17.5 (5–880) (n = 38)	0.0124

^aKolmogorov-Smirnov two-sample test.